Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which eczema drug wins? a Head-to-Head test aims to find out

NCT ID NCT06937788

Disease control Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial compares two approved eczema drugs, upadacitinib and dupilumab, in people with moderate-to-severe atopic dermatitis. Researchers will measure how well each drug clears the skin and improves quality of life, including itch and sleep. The study aims to confirm earlier findings that upadacitinib may work faster, while also checking patient-reported outcomes. Participants will receive either a daily upadacitinib pill or a dupilumab injection every other week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib and dupilumab
What this could lead to
If it works, this could confirm which of two existing eczema drugs works better for clearing skin and improving quality of life, helping doctors choose the right treatment.
What could go wrong
This is a replication study, so it may simply confirm what is already known. Results may not apply to all patients, and both drugs carry risks like infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

210 people

The number who actually took part.

Started

Aug 2021

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult subjects with moderate to severe atopic dermatitis enrolled in the TREATgermany disease registry who are candidates for systemic therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic AD with onset of symptoms at least 3 years prior to baseline * Meets UK working party criteria * EASI score ≥ 16 * ≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit Exclusion Criteria: * contraindications according to upadacitinib or dupilumab labeling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Center for Evidence Based Health Care

    Dresden, Saxony, 01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.